HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

NCT04452149

Heart Failure NYHA Class II Heart Failure NYHA Class III

COMPLETED NA

PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing

NCT00409916

Heart Failure, Congestive

UNKNOWN PHASE4

PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure

NCT00279955

Heart Failure, Congestive

COMPLETED

Reveal LINQ™ Heart Failure

NCT02758301

Heart Failure

COMPLETED

Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)

NCT00206843

Heart Failure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of research is to test, adapt, refine and validate the HEMOTAG® system to be used outside the usual medical care environments to reduce hospital readmissions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure (HF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Randomized Standard of Care

Standard of Care

Group Type NO_INTERVENTION

No interventions assigned to this group

Randomized Standard of Care with HEMOTAG

Standard of Care with HEMOTAG

Group Type ACTIVE_COMPARATOR

Standard of Care with Hemotag

Intervention Type DIAGNOSTIC_TEST

Comparison of outcomes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care with Hemotag

Comparison of outcomes

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Standard of Care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 22 years old.
* An index hospital admission for ADHF presenting with symptoms, clinical signs, and chest x-ray (CXR) findings of pulmonary congestion, receiving IV diuretics or vasoactive drugs and having a BNP \> 350 or NT-pro BNP \> 1800 pg/ml.
* Able to give informed consent.
* Participant's residence has adequate cellular data coverage.
* Participants with previous diagnosis of left ventricular ejection fraction (LVEF) \<40% prior to the index hospitalization must have been treated for at least 90 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contraindicated) and an ACE inhibitor or ARB or ARNi (unless intolerant or contraindicated).

Exclusion Criteria

* Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)
* Terminal condition with life expectancy less than 6 months as determined by investigator.
* Participants with cardiac tamponade or constrictive pericarditis.
* Participants with left ventricular assistance device (LVAD device) or had a cardiac transplantation or listed for transplantation.
* Implantation of a CRT (cardiac resynchronization therapy) device during index hospitalization or intent to implant a CRT device.
* Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation, as determined by investigator.
* Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis, as determined by investigator.
* Severe primary pulmonary, renal or hepatic disease, as determined by investigator.
* Women of childbearing age (Age \<50).
* History of pulmonary embolism of less than 3 months.
* Dialysis dependent or dialysis initiation expected within three months.
* Chronic home IV therapy or cardiac inotropes or diuretics.
* Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.
* Illness/ Condition which may be aggravated or cause significant discomfort by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).
* Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment.
* Congenital heart malformations (Complex, or uncorrected congenital heart disease).
* Participant enrolled in another interventional study (observational or registries are not excluded).
* Participant HF is managed remotely with another monitoring device or program (for example: Pulmonary/ Lt Atrial pressure monitoring, lung fluid monitoring. BNP/pro-BNP or bioimpedance or ICD or biventricular pacemaker with impedance monitoring will be allowed unless it is part of another research protocol).
* Prisoners and wards of the state.
* Inability to provide informed consent (Must speak English or Spanish or Creole).

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No